This page will attempt to capture links to doctors and organisations that are actively assisting with recovering patients who have suffered from COVID-19 vaccine injury.

Where to start?

Start by listening to the FLCCC doctors from around July-Aug 2022:

• Dr Paul Marik – HERE
• Dr Pierre Kory – HERE

Recovery Resource links

FLCCC iRECOVER – HERE

ReAct-19 – via HERE

World Council for Health: Spike Protein Detox Guide – HERE

Expose News: A List of Post-Vaccination Resources – HERE

Articles in reverse chronological order

2023

September 13, 2023 – Phillip Altman Substack: SPIKE PROTEIN DETOX – The toxic Spike Protein produced by the COVID injections linger for months – READ

• THREE MECHANISMS OF COVID “VACCINE” TOXICITY
  • TOXIC SPIKE PROTEIN (subacute risk)
  • CONTAMINATING ENDOTOXINS – (acute risk)
  • GENOTOXICITY (longer term risk)

August 31, 2023 – Courageous Discourse Substack: Bio-Pharmaceutical Censorship Complex Attacks Spike Detoxification Protocol – Syndicate Fact Checkers Confirm Empiric Regimen is Valuable for Post-Acute Sequelae after SARS-CoV-2 Infection and COVID-19 Vaccination – READ

August 23, 2023 – J. Am. Physicians & Surgeons: Clinical Rationale for SARS-CoV-2 Base Spike Protein Detoxification in Post COVID-19 and Vaccine Injury Syndromes – McCullough et al – PDF, Substack – READ

June 2023 – Better Way Workshops: An Approach to Vaccine Injury – – WATCH, CREDIT

• In this exclusive workshop, Dr Paul Marik and Dr Sarah Myhill share their extensive knowledge of what people can do to help recover from spike-induced vaccine injury

The post Help to Recover from Vaccine Injury first appeared on Totality of Evidence.

TGA: PAXLOVID: nirmatrelvir 150 mg tablet and ritonavir 100 mg tablet blister composite pack.

ClinicalTrials.gov: Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR) – HERE

People take paxlovid after they contract COVID-19 (lab confirmed PCR positive) intending to lessen symptoms and lower the chance for hospitalisation. Event for people who have been vaccinated or boosted!

According to the CDC: “Paxlovid is a prescription oral antiviral drug that reduces the risk of hospitalisation and death for patients with mild-to-moderate COVID-19 who are at risk of disease progression and severe illness. Treatment should be initiated as soon as possible and within 5 days of symptom onset among persons eligible to receive the treatmetn under the EUA.” [This timing sounds a lot like what Dr Zelenko was recommending for HCQ+zinc in early 2020]

A full treatment course of paxlovid involves taking 30 pills during a 5 day period @ approx USD$529/treatment
(Hydroxychloroquine plus zinc treatment would be far less than $20!)

FDA Fact Sheet for Paxlovid – HERE
Pfizer: How a Coronavirus Protease Inhibitor Works to Fight COVID-19 – READ
Pfizer Press Releases on Paxlovid – HERE

Paxlovid info in reverse chronological order

2023

July 7, 2023 – Dr McCullough | Courageous Discourse Substack: FDA Grants Paxlovid Full Approval but Patients Prefer Ivermectin-Based Multidrug Protocols- Three Years of COVID-19 Home Regimens Have Greater Public Confidence than Government Recommended Monotherapy – READ & WATCH

• “Emily Harris, writer for JAMA reported on June 7, 2023, that the US FDA fully approved Paxlovid for the acute ambulatory treatment of COVID-19. Paxlovid is dosed from a bubble pack: 2 tabs nirmatrelvir 300 mg plus 1 tab ritonavir 100 mg taken every 12 hours for 5 days. In the video I remind you that the CDC has a public health advisory on Paxlovid rebound or prolongation of the syndrome. Additionally, I review the issue of drug-drug interactions while taking Paxlovid.’

June 5, 2023Australia Department of Health: Protecting Older Australians – COVID-19 Update 2 June 2023 – READ, ARCHIVE

• COVID-19 Oral antiviral treatments – “Continued strong uptake of oral antiviral medications remain important in residential aged care settings. The oral antivirals Lagevrio® and Paxlovid® are available through the Pharmaceutical Benefits Scheme (PBS) for all people aged 70 years or older.”

February 22, 2023 – The Guardian: Labor MP calls on government to widen Covid anti-viral eligibility in Australia – Lagevrio and Paxlovid – READ, The drugs are “taken to reduce Covid symptoms after infection” – [isn’t that what the vaccine is meant to do?]

2022

October 27, 2022 – Clinial Trials Gov: SARS CoV-2 Viral Persistence Study (PASC) – Study of Long COVID-19 (PASC) – Paxlovid – READ, ARCHIVE, NIH – SOURCE

• “The Paxlovid trial, which is expected to begin in 2023, is part of the NIH-funded RECOVER project – Researching COVID to Enhance Recovery” – REF

October 24, 2022 – The Highwire: URGENT WARNING ON USE OF PAXLOVID – Paxlovid became the first antiviral approved for Covid from the FDA over a year ago. Now, urgent warnings of severe drug interactions with several common heart, statin and immunosuppressive medications have come to light – WATCH, FULL

October 17, 2022 – Jack C Askins MD Substack: PAXLOVID AND UNINFORMED CONSENT – Disregarding oaths and ethics – READ

• “In 40 years of writing prescriptions, I have never seen a drug with that many drug interactions and potential incompatibilities. The lengthy list of interactions represents 35 categories of drugs (not 35 drugs, but 35 categories of drugs).”

August 24, 2022 – USA Today (AP): Paxlovid, Pfizer’s COVID pill, showed no measurable benefit in adults 40 to 65, study says – re the results from a 109,000-patient Israeli study – READ, Daily Beast – READ, CREDIT

August 6, 2022 – BPR: Basement Biden still testing positive after 15 days and 4 Pfizer shots. Hmmm? [taking paxlovid & multi-jabbed]- READ, SOURCE

August 6, 2022 – Dr Malone Substack: Paxlovid Escape Mutations? – President Biden’s two and a half-week Covid-19 marathon – READ

July 31, 2022 – NBC News: Biden tests positive for Covid again, has Paxlovid rebound and no symptoms, doctor says – READ

July 30, 2022 – pResident Biden is” “rebound” COVID positive observed in a small percentage of patients treated with PAXLOVID” the White House reports, he was negative for 2 days – READ

July 29, 2022 – The Highwire Ep 278 – PAXLOVID PLAN BYPASSES DOCTORS – Dr. Pierre Kory, discusses the dangers of Paxlovid. – WATCH, FULL

July 22, 2022 – America Out Load with Dr McCullough: Vaccinated Pounded by Paxlovid Rebound – READ & LISTEN

July 21, 2022 – Bannons War Room: Dr Robert Malone: The Treatment of Joe Biden re Paxlovid problems at time of trials – WATCH, Effects of Paxlovid – WATCH

July 21, 2022 – Rebel News: NYC giving Pfizer’s Paxlovid away for free to any New Yorker who tests positive for COVID, forking millions of dollars worth of taxpayer funds to Pfizer – READ

July 14, 2022 – The Highwire Episode 276 – It Gave Fauci ‘Rebound’: What’s Going to Happen If We Keep Prescribing Paxlovid? – Dr Richard Urso – EXCERPT

July 13, 2022 – Just the News: Study finds COVID already mutating around Paxlovid, as FDA circumvents doctors to prescribe – The FDA’s expansion of the emergency use authorization (EUA) for Pfizer’s COVID-19 antiviral pill could play a role in accelerating mutations of SARS-CoV-2, new research suggests. – READ

• The FDA’s expansion of the emergency use authorization (EUA) for Pfizer’s COVID-19 antiviral pill could play a role in accelerating mutations of SARS-CoV-2, new research suggests.
• Last week, the FDA authorized state-licensed pharmacists to circumvent doctors by directly prescribing Paxlovid…
• “Apparently, someone in government decided that there wasn’t enough Paxlovid being prescribed” seven months after its approval, Philadelphia cardiologist Anish Koka wrote skeptically in his newsletter this week. 
• The pill was initially submitted to treat people who balked at COVID vaccination, but the FDA approved it for “mild-to-moderate” infections in people at high risk of developing severe COVID, as young as 12, regardless of vaccination status. “
• The COVID rebound phenomenon wasn’t disclosed in Pfizer’s peer-reviewed paper on the nirmatrelvir trial, only showing up in the FDA’s EUA documents, Koka said. …”98% of placebo recipients not developing severe COVID”.

“Pfizer will make $20 billion+ from this drug, and they still have not provided a positive randomized trial in vaccinated people,“

Vinay Prasad epidemiologist (July 8, 2022)

July 10, 2022 – Anish Koka substack – Pharmacists Can Now Prescribe Paxlovid. Good idea? – READ

July 4, 2022 – Preprint: SARS-CoV-2 3CLpro mutations confer resistance to Paxlovid (nirmatrelvir/ritonavir) in a VSV-based, non-gain-of-function system , Heilmann et al – PDF

June 30, 2022 – PRESS RELEASE: Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID – for individuals at high risk for progression to severe illness from COVID-19 – READ

June 30, 2022 – New York Times: New York City Will Offer Paxlovid at Mobile Testing Sites, a First in the U.S. – READ

–

“New York City is creating the first mobile testing units in the United States that will allow people who test positive for the coronavirus to immediately receive for free the antiviral treatment Paxlovid” REASON: “help address concerns over inequities in distributing antiviral treatments.”

June 14, 2022 – Pfier: Pfizer Reports Additional Data on PAXLOVID Supporting Upcoming New Drug Application Submission to U.S. FDA – READ

• “just a handful of hospitalizations or deaths separated placebo recipients from those who took Paxlovid, including in a vaccinated subgroup. The drugmaker characterized the benefits as “non-significant.”” – source
• ERGO: Paxlovid trial stopped for lack of efficacy in standard risk patients. Coronavirus can find multiple ways to evade COVID-19 drug – Dr Malone – source

June 6, 2022 – PRESS RELEASE: Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S – PAXLOVID. – READ

June 2, 2022 – Epoch Times Facts Matter – CDC Issues Warning on Pfizer’s Covid Pills, Alerts Issued For “Covid Rebound” and Positive Viral PCR Tests – WATCH

• Watch above as Roman Balmokov takes you through Paxlovid’s story, what it is and how it works. He notes that before EUA was issued the Biden administration payed $5.3 billion contract with Pfizer upfront agreeing to 10million tmt courses of the pills working out to $529/treatment.
• COVID-19 rebound [feeling sick, the thing the drug was meant to prevent!] did not represent reinfection with SARS-CoV-2 or the development of resistance to Paxlovid – this was something known from the clinical trials.

May 24, 2022 – CDC issues an advisory warning: COVID-19 Rebound After Paxlovid Treatment – HERE

May 9, 2022 – Medicine with Dr Moran: Pfizer cashing in on COVID Drug Paxlovid- Was it helpful for VP Harris? Is Pfizer being Transparent? – WATCH

May 4, 2022 – John Campbell looks at Paxlovid evidence? – WATCH

April 29, 2022 – PRESS RELEASE: Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID for Post-Exposure Prophylactic Use – READ (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis = EPIC-PEP)

April 14, 2022 – NEJM: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – Hammond et al – PAPER

• “Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M^pro) inhibitor with potent pan–human-coronavirus activity in vitro.” – this is the clinical trail that FDA EUA was based when Delta variant was in circulation.

March 22, 2022 – PRESS RELEASE: Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries – READ

March 21, 2022 – Precision vaccinations: What is Paxlovid’s Absolute and Relative COVID-19 Risk Reduction – READ

March 9, 2022 – PRESS RELEASE: Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants – PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) is the first oral therapy specifically designed to combat COVID-19 to be evaluated in a pediatric clinical study – READ

January 19, 2022 – Epoch Times: Australia Approves Novavax COVID-19 Vaccine and New COVID Oral Drug Treatments (Paxlovid and Lagevrio) – READ

• TGA has also approved the first anti-viral pills, Pfizer’s Paxlovid and Merck Sharp & Dohme’s Lagevrio but stressed that they are not a substitute for vaccinations….The pills are designed to prevent a patient’s condition from progressing to a more severe stage and work by interfering with the virus’s ability to multiply within the patient’s body.

January 20, 2022 – Australia’s Therapeutic Goods Administration (TGA): TGA provisionally approves two oral COVID-19 treatments, molnupiravir (LAGEVRIO) and nirmatrelvir + ritonavir (PAXLOVID) – READ

January 18, 2022 – Pfizer press release: Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant – READ

January 18, 2022 – Australia’s Therapeutic Goods Administration (TGA): TGA provisionally approves Pfizer Australia Pty Ltd’s COVID-19 treatment nirmatrelvir + ritonavir (PAXLOVID) – READ, Provisional treatments, TGA summary on Paxlovid, axlovid regulatory documents – HERE

• “The decision has been made on the basis of short term efficacy and safety data. Continued approval of this indication depends on the efficacy and safety data from ongoing clinical trials and post-market assessment.”

January 4, 2022 – PRESS RELEASE: Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19 – READ

2021

December 22, 2021 – PFIZER PRESS RELEASE: Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment – PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) – READ

December 22, 2021 – FDA EUA press release: Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19 – LINK, FDA FACT SHEET –

December 14, 2021 – Pfizer press release: Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death – READ Data not delivered 5 month later – WATCH

November 5, 2021 – PRESS RELEASE: Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study – 28 day study – READ

November 2021 – TGA: PAXLOVID by Pfizer was Accepted for evaluation For treatment of COVID-19 – LINK, SCREENSHOT,

5 October 2021 -TGA grants “Provisional Determination” for Paxlovid, this authorises the drug to move through the Provisional Approval assessment process – READ

2020

October 2020 – Journal of Clinical Pharmacy and Therapeutics: QTc prolongation during antiviral therapy in two COVID‐19 patients by Zhu et al – READ lopinavir/ritonavir, CREDIT

• “In fact, Lopinavir/ritonavir (Paxlovid), used to treat Covid, has an established QT prolongation effect like HCQ, but since warnings about drug-drug interactions are well-publicized and Paxlovid is dispensed under physician/pharmacist supervision, reported cardiac adverse events are uncommon, avoiding cardiac and other safety concerns. ” – (2024) REF

The post Paxlovid by Pfizer first appeared on Totality of Evidence.

Repurposing known, cheap, off-patent drugs, singularly or in combinations, has been much of their focus.  Drugs with already know side-effect and toxicity profiles.  Drugs that are cheap, because the are off-patent, and have no “commercial value”.  Drugs that when they tried them, have literally been life saving and prevented the need for tens of thousands of hospitalisations, which was the whole purpose of the March 2020 global lockdowns – flatten the curve!

Health authorities designed clinical trials to assess the “potential” of therapeutics in hospitalised patients only, they used doses that exceeded known toxic levels, and they didn’t do combination drug therapies! At least this is true for HCQ in the first 9 months of the pandemic.

Later in the pandemic, they carried out a few outpatient treatment trials again not in combination, just single drugs.  Though the Oxford randomised budesonide study they had to cut short, because the treatment was so successful, they couldn’t ethically keep it from the control group. The same is true for ivermectin.

Early treatments have been largely ignored, why?

Early treatment options have seemingly been ignored by the “health authorities”, and poorly challenged by the main stream media.  There has been a strong push from the start of the pandemic that a vaccine will be the only solution!

The information about early treatment options is available, you just need to know where to look as it has been suppressed by Big Tech and the media.   Unknown “fact checkers” deemed it dis-information.  Judge for yourself.  Take the time to investigate yourself.

December 17, 2020 – Leon Klein: AFFORDABLE AND EFFECTIVE EARLY TREATMENTS – A summary overview – WATCH

Multidrug-therapy for high-risk patients has resulted in 85% reductions in COVID-19 hospitalization and death*.

*McCullough PA, Alexander PE, Armstrong R, et al. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Rev Cardiovasc Med (2020) 21:517–530. doi:10.31083/j.rcm.2020.04.264.  Link to paper here.

Treatment resources

There are many websites that are aggregating trial results, protocols and testimony from front line doctors and scientific specialists.  As we find these links we’ll add them to this page.

The Science data – C19 early – COVID-19 early treatment: real-time analysis – HERE

COVID-19 Protocols:

C19 Protocols website contains links to:

• Early Treatment Protocols,
• Prevention Protocols,
• Long-haul COVID-19 Protocols,
• Scientific studies and more

The above site is complied by front line doctors, those who are actually treating patients.

Early COVID Care – HERE,

FLCCC i-CARE early treatment protocols – HERE

WHO: Therapeutics and COVID-19: living guideline – April 2022 – ARCHIVE

Treatment Summaries

• Multi-drug approach – video and paper
• Budesonide
• Hydroxychloroquine
• Ivermectin
• Vitamin C and video and link and resource
• Vitamin D
• CDS , Preparation, Clinical trial here  Published here

Studies demonstrating the efficacy of COVID-19 treatments – Evidence by drug group @ early COVID care – HERE

Protocols Links

In no particular order

Prevention Protocols

Treatment Protocols

America’s Frontline Doctors – videos

Medicine (un)censored by James Todaro MD

Zelenko prophylaxis protocol

COVID-19 How can I cure thee? Let me count the ways  by Dr Thomas Levy

Official treatment guidelines

May 27, 2020 – WHO Intrim Guidance: Clinical management of COVID-19 – READ, ARCHIVES

Other Treatment Options

2023

July 29, 2023 – Courageous Discourse Substack: The Clear Benefits of Nasal Hygiene an interview with Mr. Nathan Jones, CEO of XLEAR nasal spray – WATCH & READ

• “Decades ago, Nate’s father, Dr. Alonzo Jones, began an exhaustive study of the benefits of oral and nasal hygiene for preventing upper respiratory tract infections. Nate found his father’s research so compelling that he formulated a nasal spray based on Dr. Jones’s findings”
• “…multiple lab tests confirmed that a minor component of XLEAR nasal spray—i.e., its grapefruit seed extract preservative—destroys SARS-CoV-2“
• “…the Federal Trade Commission prohibited every company in the nasal hygiene space from making any claims about the benefit of their products in preventing SARS-CoV-2 infection, reducing its severity, or reducing its transmissibility.”…”in spite of numerous peer-reviewed studies in the medical literature showing that viricidal nasal rinses can indeed reduce the duration and severity of the illness” – inorder to get EUA on mRNA jabs!
  • FTC sued XLEAR in court – READ, the fight is ongoing.

July 27, 2023 – Meryl Nass Substack: Treating COVID-19 in 2023 and update ivermecting and hydroxychloroquine – READ, i-CARE protocols – HERE

2022

August 2, 2022 – Journal of Pharmacy & Pharmacology Research: The Problem of Home Therapy during COVID-19 Pandemic in Italy: Government Guidelines versus Freedom of Cure? – Fazio et al – READ, PDF
Working group concluded there was obstruction to home-based therapies for COVID-19. – GETTR

July 20, 2022 – Dr Paul Alexander Substack: Nitric Oxide Nasal Spray (NONS) lowers Covid viral load by 94 per cent in 24 hours: Lancet study; Nitric Oxide blocks entry into nasal passage, kills the virus and stops its replication – READ

April 22, 2022 – WHO: Therapeutics and COVID-19: living guideline – ARCHIVE, Gilead press release – READ

• Early treatment with remdesivir recommended but at no time should hydroxychloroquine be used.

April 14, 2022 – Steve Kirsch Substack: These people deserve the credit for the deaths of nearly a million Americans – Introducing the members of the NIH COVID-19 Treatment Guidelines committee. – “if there are 100 trials and 90% of the trials were positive and 10% were neutral, should the NIH recommend the drug?” – READ

2020

December 30, 2020 – Reviews in Cardiovascular Medicine: Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) by McCullough et al – ARCHIVE, READ

October 11, 2020 – Association of American Physicians and Surgeons: Ambulatory Treatment of COVID-19 – WATCH, PAPER, SLIDES

August 26, 2020 – The Texan: Dallas Cardiologist Offers Guidance on Early Treatment of COVID-19 – To provide guidance to doctors about early treatment of coronavirus, cardiologist Dr. Peter McCullough wrote an article that will soon be published in the American Journal of Medicine – READ, Dr Peter McCullough – MORE

March 17, 2020 – International Society for Orthomolecular Medicine (ISOM) recommends nutrition support for curing and treating new coronavirus infections – WATCH, READ

The post COVID-19 Early Treatment Protocols first appeared on Totality of Evidence.